Clinical Trials for Melanoma

An Open-Label Phase 1/2A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Advanced and/or Refractory Solid Tumor Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, progressive advanced solid tumors and no suitable standard therapy receive GV20-0251 alone or with pembrolizumab; expansion cohorts focus on selected tumor types, including melanoma, NSCLC, head and neck and endometrial cancers, and pMMR/MSS colorectal cancer in combination cohorts. GV20-0251 is an investigational antibody targeting IGSF8, a proposed innate immune checkpoint.

ClinicalTrials.gov ID: NCT05669430

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects With Advanced/Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated, unresectable advanced or metastatic solid tumors and ECOG performance status 0–1 receive intravenous DB-1311/BNT324 every 21 days in dose-escalation or tumor-specific expansion cohorts. DB-1311/BNT324 is an investigational B7-H3–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload; prior B7-H3–targeted therapy or a topoisomerase inhibitor–payload ADC is excluded.

ClinicalTrials.gov ID: NCT05914116

An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors and ECOG 0–1 receive GI-102 alone or with selected anticancer agents; a dose-optimization cohort focuses on checkpoint inhibitor–refractory metastatic melanoma after at least one prior line of therapy. GI-102 is an investigational CD80–IL-2 variant fusion protein designed to block CTLA-4 signaling and stimulate CD8 T and natural killer cells; combination partners include doxorubicin, paclitaxel/bevacizumab, eribulin, pembrolizumab, and trastuzumab deruxtecan.

ClinicalTrials.gov ID: NCT05824975

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that progressed after at least 3 months of pembrolizumab, and who have no effective treatment options, receive oral PLN-101095 alone or with continued pembrolizumab. PLN-101095 inhibits αvβ8 and αvβ1 integrins to reduce activation of immunosuppressive TGF-β in the tumor microenvironment.

ClinicalTrials.gov ID: NCT06270706

A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab, Cetuximab or FOLFIRI Plus Cetuximab in Patients With Advanced Solid Refractory/Resistant Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic refractory/resistant solid tumors, including selected colorectal, head and neck, lung, breast, renal, and acral melanoma cohorts, receive TTX-080, an investigational HLA-G–blocking antibody, alone or with pembrolizumab, cetuximab, or FOLFIRI plus cetuximab. A colorectal cancer cohort compares FOLFIRI plus cetuximab with or without TTX-080.

ClinicalTrials.gov ID: NCT04485013

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This single-arm study enrolls patients aged 1–21 with recurrent or refractory solid tumors, non-Hodgkin lymphoma, or desmoid tumors, with expansion cohorts for selected tumors and Wnt-pathway aberrations extending eligibility to age 30. Patients receive IV tegavivint on days 1, 8, and 15 of each 28-day cycle; it targets TBL1 to disrupt β-catenin–dependent Wnt signaling.

ClinicalTrials.gov ID: NCT04851119

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients with Advanced Cancer with and Without Pembrolizumab

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable, locally advanced or metastatic solid tumors and ECOG 0–1, generally without remaining standard options, receive oral LNS8801 alone or with pembrolizumab; disease-specific cohorts include melanoma, pancreatic, gastric, NSCLC, and colorectal cancers. LNS8801 is an investigational selective agonist of the G protein-coupled estrogen receptor (GPER), and pembrolizumab is an anti-PD-1 antibody.

ClinicalTrials.gov ID: NCT04130516

A Phase 1/2 Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic uveal melanoma or other measurable solid tumors harboring GNAQ/GNA11 mutations or PRKC fusions receive darovasertib (IDE196), an oral PKC inhibitor, alone or with the MEK inhibitor binimetinib or the MET/ALK/ROS1 inhibitor crizotinib. Eligibility requires ECOG performance status 0–1; prior PKC inhibitor treatment is excluded.

ClinicalTrials.gov ID: NCT03947385

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients aged 21 years or younger with measurable, B7-H3–positive solid tumors that have relapsed or are refractory after first-line therapy receive lymphodepleting fludarabine and cyclophosphamide followed by a single infusion of autologous CAR T cells engineered to target B7-H3 (CD276) on tumor cells.

ClinicalTrials.gov ID: NCT04897321

A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic uveal melanoma or unresectable/metastatic undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma receive personalized autologous tumor-infiltrating lymphocytes (lifileucel, LN-144/LN-145) after tumor excision and lymphodepleting chemotherapy, followed by interleukin-2. Sarcoma patients generally must have received prior systemic therapy; the infused lymphocytes may recognize multiple tumor antigens rather than a single specified target.

ClinicalTrials.gov ID: NCT05607095